Novartis has reported net income of $2.9 billion for the second quarter of 2017 which is a slight decrease comparing the same period last year.
The company’s half year result is $5.6 billion, also slight decrease, comparing last years $5.7billion.
Joseph Jimenez, CEO of Novartis, commented: “Novartis delivered very strong innovation in Q2 including the positive pivotal trial readouts for RTH258, ACZ885 and CTL019 JULIET, demonstrating the strength of our pipeline. We are on track for the full year guidance. The trajectory of the current growth drivers reinforces our confidence in our next growth phase, which we expect to start in 2018.”